Evicenter
Skyrizi (risankizumab-rzaa) in Plaque psoriasis
Manufacturer
AbbVie Inc.
Prescribing information
Skyrizi (opens in a new tab)
Questions
47
Last updated

All questions

Dosing and administration: Skyrizi (risankizumab-rzaa) in plaque psoriasis

7 questions · 5 sources

Switching

What happens when patients switch to Skyrizi from Stelara (ustekinumab)?

Applies to Adults with moderate-to-severe plaque psoriasis

Note: The 73% figure is in the section of the comparison page on patients switched from blinded ustekinumab to open-label Skyrizi; the page text gives no denominator, and the page gives the PASI 90 rate of these patients before the switch only in a chart. The 73% is a last-observation-carried-forward result in the open-label extension sub-analysis, which includes only patients who completed UltIMMa-1 or -2 and enrolled in LIMMitless. The switch data are not in the Prescribing Information; the page cites Strober et al., EADV 2019.

Does switching to Skyrizi help Humira (adalimumab) patients who did not reach PASI 90?

Applies to Adults with moderate-to-severe plaque psoriasis

Note: Part B included only Humira patients with PASI 50 to <90 at Week 16. IMMvent is not described in the Skyrizi Prescribing Information; the result is from the comparison page of the Skyrizi HCP site, which cites Reich et al., Lancet 2019. The page text gives no denominators for these rates.

Dosing

Does the Skyrizi dose depend on body weight?

What is the Skyrizi dosage for plaque psoriasis?

Administration

How and where is Skyrizi injected?

Can patients inject Skyrizi themselves?

Is the Skyrizi pen bioequivalent to the prefilled syringe?